Insight

Joshua D. Palmer: TURBO-NSCLC study looking at TKI alone or combination with SRS for brain metastasis

Photo taken from Joshua D. Palmer/X

Jul 28, 2024, 15:37

Joshua D. Palmer: TURBO-NSCLC study looking at TKI alone or combination with SRS for brain metastasis

Joshua D. Palmer, Radiation Oncologist and Associate Professor at The Ohio State University Wexner Medical Center, shared a post on X about a recent paper by Luke R.G. Pike et al., commenting:

“Check out the TURBO-NSCLC study looking at Up-Front next generation Tyrosine kinase inhibitors (TKI) alone or combination with Stereotactic radiosurgery (SRS) for brain metastasis. We found that combination with SRS had better local control and time to progression especially for lesions >1cm.”

Tyrosine Kinase Inhibitors with and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC) published in ASCO Publications.

Authors: Luke R.G. Pike, Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall, Erqi L. Pollom, Caressa Hui, Vera Qu, Jacob Langston, Veronica Chiang, Michael Grant, Sarah B. Goldberg, Joshua D. Palmer, Rahul N. Prasad, Tony J.C. Wang, Albert Lee, Catherine A. Shu, Lanyi Nora Chen, Nicholas J.Thomas, Steve E. Braunstein, Brian D.Kavanagh, D. Ross Camidge, and Chad G.Rusthoven.

Joshua D. Palmer

Additional information
Source: Joshua D. Palmer/X

cancer Joshua D. Palmer OncoDaily Oncology Stereotactic radiosurgery (SRS) The Ohio State University Wexner Medical Center TURBO-NSCLC tyrosine kinase inhibitors (TKI)

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage